Constant drug dose in human immuno-deficiency virus-infected patients to induce long-term nonprogressor status: Bifurcation and controllability approach

Wonhee Kim, Han Byul Chung, Choo Chung Chung

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The authors propose a therapy consisting of a constant dosage of reverse transcription inhibitor and protease inhibitor to achieve long-term non-progressor (LTNP) status in human immuno-deficiency virus (HIV) patients. Based on the authors analyses of cytotoxic T lymphocyte precursor (CTLp) concentration at several equilibrium points and the bifurcation of these equilibrium points, they find that administration of drugs with an efficacy lower than a certain level induces a higher CTLp concentration. As a result, drug doses of moderate efficacy result in more patients with LTNP status than doses with high efficacy. In analyses of controllability, they show that a treatment of moderate efficacy is more efficient than one of very high efficacy in terms of controlling the immune system. Using simulations, they demonstrate that their proposed method results in LTNP status in HIV patients.

Original languageEnglish
Pages (from-to)79-88
Number of pages10
JournalIET Systems Biology
Volume7
Issue number3
DOIs
StatePublished - 2013 Dec 1

Fingerprint

T-cells
Controllability
Viruses
Virus
Efficacy
Dose
Drugs
Bifurcation
Cytotoxic T-Lymphocytes
Immune system
Transcription
T Lymphocytes
Pharmaceutical Preparations
Equilibrium Point
Precursor
Inhibitor
Protease Inhibitors
Reverse Transcription
Immune System
Protease

Cite this

@article{a09d0bcfbc444d0c9895ff2b6e4238dd,
title = "Constant drug dose in human immuno-deficiency virus-infected patients to induce long-term nonprogressor status: Bifurcation and controllability approach",
abstract = "The authors propose a therapy consisting of a constant dosage of reverse transcription inhibitor and protease inhibitor to achieve long-term non-progressor (LTNP) status in human immuno-deficiency virus (HIV) patients. Based on the authors analyses of cytotoxic T lymphocyte precursor (CTLp) concentration at several equilibrium points and the bifurcation of these equilibrium points, they find that administration of drugs with an efficacy lower than a certain level induces a higher CTLp concentration. As a result, drug doses of moderate efficacy result in more patients with LTNP status than doses with high efficacy. In analyses of controllability, they show that a treatment of moderate efficacy is more efficient than one of very high efficacy in terms of controlling the immune system. Using simulations, they demonstrate that their proposed method results in LTNP status in HIV patients.",
author = "Wonhee Kim and Chung, {Han Byul} and Chung, {Choo Chung}",
year = "2013",
month = "12",
day = "1",
doi = "10.1049/iet-syb.2012.0006",
language = "English",
volume = "7",
pages = "79--88",
journal = "IET Systems Biology",
issn = "1751-8849",
number = "3",

}

TY - JOUR

T1 - Constant drug dose in human immuno-deficiency virus-infected patients to induce long-term nonprogressor status

T2 - Bifurcation and controllability approach

AU - Kim, Wonhee

AU - Chung, Han Byul

AU - Chung, Choo Chung

PY - 2013/12/1

Y1 - 2013/12/1

N2 - The authors propose a therapy consisting of a constant dosage of reverse transcription inhibitor and protease inhibitor to achieve long-term non-progressor (LTNP) status in human immuno-deficiency virus (HIV) patients. Based on the authors analyses of cytotoxic T lymphocyte precursor (CTLp) concentration at several equilibrium points and the bifurcation of these equilibrium points, they find that administration of drugs with an efficacy lower than a certain level induces a higher CTLp concentration. As a result, drug doses of moderate efficacy result in more patients with LTNP status than doses with high efficacy. In analyses of controllability, they show that a treatment of moderate efficacy is more efficient than one of very high efficacy in terms of controlling the immune system. Using simulations, they demonstrate that their proposed method results in LTNP status in HIV patients.

AB - The authors propose a therapy consisting of a constant dosage of reverse transcription inhibitor and protease inhibitor to achieve long-term non-progressor (LTNP) status in human immuno-deficiency virus (HIV) patients. Based on the authors analyses of cytotoxic T lymphocyte precursor (CTLp) concentration at several equilibrium points and the bifurcation of these equilibrium points, they find that administration of drugs with an efficacy lower than a certain level induces a higher CTLp concentration. As a result, drug doses of moderate efficacy result in more patients with LTNP status than doses with high efficacy. In analyses of controllability, they show that a treatment of moderate efficacy is more efficient than one of very high efficacy in terms of controlling the immune system. Using simulations, they demonstrate that their proposed method results in LTNP status in HIV patients.

UR - http://www.scopus.com/inward/record.url?scp=84885810290&partnerID=8YFLogxK

U2 - 10.1049/iet-syb.2012.0006

DO - 10.1049/iet-syb.2012.0006

M3 - Article

C2 - 24046977

AN - SCOPUS:84885810290

VL - 7

SP - 79

EP - 88

JO - IET Systems Biology

JF - IET Systems Biology

SN - 1751-8849

IS - 3

ER -